Presentation is loading. Please wait.

Presentation is loading. Please wait.

Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma  Eric D. Bateman, MD, Udo-Michael.

Published byMarianne Groth Modified over 5 years ago

Similar presentations

Presentation on theme: "Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma  Eric D. Bateman, MD, Udo-Michael."— Presentation transcript:

1 Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma  Eric D. Bateman, MD, Udo-Michael Goehring, MD, Frank Richard, MD, Henrik Watz, MD  Journal of Allergy and Clinical Immunology  Volume 138, Issue 1, Pages e8 (July 2016) DOI: /j.jaci Copyright © 2016 The Authors Terms and Conditions

2 Fig 1 Schematic of the crossover study design: 2- to 4-week screening period, followed by two 4-week double-blind treatment periods separated by a washout period of 4 weeks. A final visit took place 7 to 21 days after the second treatment period. QD, Once daily. Journal of Allergy and Clinical Immunology  , e8DOI: ( /j.jaci ) Copyright © 2016 The Authors Terms and Conditions

3 Fig 2 Disposition of patients. A, Roflumilast (500 μg) plus montelukast (10 mg) once daily (QD). B, Placebo plus montelukast (10 mg) QD. Journal of Allergy and Clinical Immunology  , e8DOI: ( /j.jaci ) Copyright © 2016 The Authors Terms and Conditions

4 Fig 3 A, Mean (SD) change from baseline in prebronchodilator FEV1 (in liters) in treatment periods 1 and 2 (full analysis set). B, Mean (SD) change from baseline to week 4 in FVC in treatment periods 1 and 2. C, Mean change from baseline to week 4 in prebronchodilator PEF (in liters). D, Improvement (reduction) in ACQ-7 score (mean change from baseline) by visit comparing montelukast plus placebo and montelukast plus roflumilast. MCID, Minimal clinically important difference. Journal of Allergy and Clinical Immunology  , e8DOI: ( /j.jaci ) Copyright © 2016 The Authors Terms and Conditions

5 Fig 4 Changes in urinary LTE4 values (SD) during treatment sequences AB (n = 32) and BA (n = 32). A, Roflumilast (500 μg once daily) + montelukast (10 mg once daily); B, placebo plus montelukast (10 mg once daily). Mean (SD) values were measured at baseline period 1, day 28, baseline period 2, and day 84. Journal of Allergy and Clinical Immunology  , e8DOI: ( /j.jaci ) Copyright © 2016 The Authors Terms and Conditions

Download ppt "Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma  Eric D. Bateman, MD, Udo-Michael."

Similar presentations

The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5- year follow-up: Effectiveness of early intervention with budesonide in.

The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5- year follow-up: Effectiveness of early intervention with budesonide in.
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis  Fuad M. Baroody, MD, David Brown, MD,

Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis  Fuad M. Baroody, MD, David Brown, MD,
Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M

Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M
Anne M. Fitzpatrick, PhD, MSCR, W. Gerald Teague, MD 

Anne M. Fitzpatrick, PhD, MSCR, W. Gerald Teague, MD 
Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo  Eli O. Meltzer, MD, Claus Bachert,

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo  Eli O. Meltzer, MD, Claus Bachert,
The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,
Tiotropium improves lung function in patients with severe uncontrolled asthma: A randomized controlled trial  Huib A.M. Kerstjens, MD, PhD, Bernd Disse,

Tiotropium improves lung function in patients with severe uncontrolled asthma: A randomized controlled trial  Huib A.M. Kerstjens, MD, PhD, Bernd Disse,
Effect of montelukast for treatment of asthma in cigarette smokers

Effect of montelukast for treatment of asthma in cigarette smokers
Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.

Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.
Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis  Paul H. Ratner,

Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis  Paul H. Ratner,
A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma  Stanley J. Szefler, MD, Kevin Murphy,

A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma  Stanley J. Szefler, MD, Kevin Murphy,
Tiotropium add-on therapy improves lung function in children with symptomatic moderate asthma  Christian Vogelberg, MD, PhD, Michael Engel, MD, István.

Tiotropium add-on therapy improves lung function in children with symptomatic moderate asthma  Christian Vogelberg, MD, PhD, Michael Engel, MD, István.
The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial  Pierluigi Paggiaro,

The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial  Pierluigi Paggiaro,
Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo- controlled crossover park study  Peter Kenney, BSc, Ole Hilberg,

Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo- controlled crossover park study  Peter Kenney, BSc, Ole Hilberg,
Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I

Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Badrul A. Chowdhury, MD, PhD 

Badrul A. Chowdhury, MD, PhD 

Similar presentations

Ads by Google